Ascophyllan Supplementation: Randomized Pilot Assesses Safety and Exploratory Effects on Immunity and Gut Microbiome
In a 12-participant pilot trial, 28-day ascophyllan supplementation was safe, but no immunological, antioxidant, or microbiome effect survived correction for multiple comparisons.
| Population | — |
|---|---|
| Intervention | — |
| Comparator | — |
| Outcome | — |
What the study showed
No adverse events were recorded and hematologic, renal, and biochemical parameters remained stable throughout. Exploratory analyses suggested directional changes in NK-cell phenotypes (CD57+, NKp46+, NKG2D+), serum antioxidant capacity, and microbiome composition, but none retained statistical significance after multiple-comparisons correction.
How it was done
Randomized, double-blind, placebo-controlled pilot with 12 participants (6 ascophyllan, 6 placebo) over 28 days, using serial flow cytometry, total antioxidant capacity measurement, 16S rRNA sequencing, and repeated laboratory assessments.
Risk of bias
A sample of 12 participants renders the study critically underpowered to detect any effect reliably. All analyses are explicitly exploratory, with no confirmed primary hypotheses.
What this study does NOT prove
It cannot be concluded that ascophyllan effectively modulates immune function, oxidative stress, or gut microbiota in humans.
In clinical practice
The 28-day safety profile is reassuring but insufficient to guide clinical use. No biological effect was statistically confirmed.
Limitations
A sample of 12 participants renders the study critically underpowered to detect any effect reliably. All analyses are explicitly exploratory, with no confirmed primary hypotheses.
Technical appendix
Version history
- 1.0 · 2026-07-10 — Auto-generated under Evidence Standard v1.0
Paid access: structured summary from public metadata; consult the original study at the source.